BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 16699316)

  • 1. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 May; 30(5):614-24. PubMed ID: 16699316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymph node involvement in ovarian serous tumors of low malignant potential: a clinicopathologic study of thirty-six cases.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2010 Jan; 34(1):1-9. PubMed ID: 19898226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodal endosalpingiosis in ovarian serous tumors of low malignant potential with lymph node involvement: a case for a precursor lesion.
    Djordjevic B; Clement-Kruzel S; Atkinson NE; Malpica A
    Am J Surg Pathol; 2010 Oct; 34(10):1442-8. PubMed ID: 20871218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2012 Jul; 36(7):955-63. PubMed ID: 22613998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study.
    Sangoi AR; McKenney JK; Dadras SS; Longacre TA
    Am J Surg Pathol; 2008 Feb; 32(2):261-8. PubMed ID: 18223329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions.
    Emerson RE; Wang M; Liu F; Lawrence WD; Abdul-Karim FW; Cheng L
    Int J Gynecol Pathol; 2007 Oct; 26(4):387-94. PubMed ID: 17885488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
    Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
    Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
    Kennedy AW; Hart WR
    Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments on the significance and pathogenesis of lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors).
    Fadare O
    Int J Gynecol Cancer; 2009 Jan; 19(1):103-8. PubMed ID: 19258950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
    Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
    Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors.
    Takeshima N; Hirai Y; Umayahara K; Fujiwara K; Takizawa K; Hasumi K
    Gynecol Oncol; 2005 Nov; 99(2):427-31. PubMed ID: 16112718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
    Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
    Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible metaplastic origin of lymph node "metastases" in serous ovarian tumor of low malignant potential (borderline serous tumor).
    Kadar N; Krumerman M
    Gynecol Oncol; 1995 Dec; 59(3):394-7. PubMed ID: 8522262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian serous borderline tumors with invasive peritoneal implants.
    Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
    Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of lymph node involvement in ovarian serous borderline tumors.
    Lesieur B; Kane A; Duvillard P; Gouy S; Pautier P; Lhommé C; Morice P; Uzan C
    Am J Obstet Gynecol; 2011 May; 204(5):438.e1-7. PubMed ID: 21349494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micropapillary pattern in serous borderline ovarian tumors: does it matter?
    Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Nam JH
    Gynecol Oncol; 2011 Dec; 123(3):511-6. PubMed ID: 21917305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.
    Longacre TA; McKenney JK; Tazelaar HD; Kempson RL; Hendrickson MR
    Am J Surg Pathol; 2005 Jun; 29(6):707-23. PubMed ID: 15897738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.